<- Go Home
Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Market Cap
$106.4M
Volume
58.6K
Cash and Equivalents
$14.2M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$5.1M
Profit Margin
68.73%
52 Week High
$54.29
52 Week Low
$4.50
Dividend
N/A
Price / Book Value
1.84
Price / Earnings
-1.82
Price / Tangible Book Value
-21.91
Enterprise Value
$95.7M
Enterprise Value / EBITDA
N/A
Operating Income
-$22.3M
Return on Equity
83.00%
Return on Assets
-21.63
Cash and Short Term Investments
$14.2M
Debt
$3.5M
Equity
$58.3M
Revenue
$7.4M
Unlevered FCF
-$22.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium